Stockscreener 앱 받기
68.95
3.75%
2.49
시장 영업 전:
69.50
0.55
+0.80%
전일 마감가:
$66.46
열려 있는:
$67.17
하루 거래량:
2.04M
Relative Volume:
1.79
시가총액:
$4.13B
수익:
-
순이익/손실:
$-105.43M
주가수익비율:
-29.74
EPS:
-2.3183
순현금흐름:
$-88.42M
1주 성능:
-6.81%
1개월 성능:
+29.34%
6개월 성능:
+152.47%
1년 성능:
+590.88%
1일 변동 폭
$65.00
$69.28
1주일 범위
$60.98
$76.37
52주 변동 폭
$8.91
$91.00
Oruka Therapeutics Inc Stock (ORKA) Company Profile
명칭
Oruka Therapeutics Inc
전화
650-606-7910
주소
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
68.95 | 3.98B | 0 | -105.43M | -88.42M | -2.3183 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Piper Sandler | Overweight |
| 2025-11-13 | 개시 | Jefferies | Buy |
| 2025-10-27 | 개시 | Guggenheim | Buy |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-05-22 | 개시 | BTIG Research | Buy |
| 2025-02-04 | 개시 | Wolfe Research | Outperform |
| 2024-10-11 | 개시 | Stifel | Buy |
| 2024-10-07 | 개시 | H.C. Wainwright | Buy |
| 2024-09-17 | 개시 | Leerink Partners | Outperform |
| 2024-09-16 | 개시 | TD Cowen | Buy |
| 2024-09-13 | 개시 | Jefferies | Buy |
| 2018-02-27 | 개시 | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 개시 | Dawson James | Buy |
모두보기
Oruka Therapeutics Inc 주식(ORKA)의 최신 뉴스
Oruka Therapeutics shares jump on strong psoriasis trial results - MSN
Fairmount funds keep 19.99% Oruka (ORKA) stake under 45-day lock-up - Stock Titan
Assessing Oruka Therapeutics (ORKA) Valuation After Phase 2a Psoriasis Success And Once‑Yearly Dosing Potential - Sahm
Oruka Therapeutics Insider Sold Shares Worth $319,384, According to a Recent SEC Filing - marketscreener.com
ORKA SEC FilingsOruka Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Oruka Therapeutics COO Laura Sandler sells $319,384 in Orka shares By Investing.com - Investing.com Canada
Oruka Therapeutics COO Laura Sandler sells $319,384 in Orka shares - Investing.com
Oruka Therapeutics (ORKA) COO sells 5,000 shares and exercises 5,000-share warrant - Stock Titan
Oruka Therapeutics Completes Public Equity Offering Under Shelf - The Globe and Mail
Three biotechs raise $850M+ in upsized IPOs, gain in aftermarket: Public Equity Report - biocentury.com
Finance Watch: Avalyn, Hemab And Seaport Launch $856m Worth Of IPOs - Citeline News & Insights
Laura Sandler to sell 10,000 ORKA shares (ORKA) via option exercise - Stock Titan
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 5.9%Here's Why - MarketBeat
Q2 EPS Estimate for Oruka Therapeutics Boosted by Analyst - MarketBeat
Oruka Therapeutics prices upsized $700M public offering at $72.50 per share - MSN
Oruka Therapeutics (ORKA) price target increased by 34.40% to 91.96 - MSN
Oruka Therapeutics (ORKA) sells 9.66M shares at $72.50 in underwritten deal - Stock Titan
Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001 - Yahoo Finance
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Up 22.4% in April - MarketBeat
Oruka Therapeutics, Inc. (ORKA) Discusses Interim Results From EVERLAST-A Study of ORKA-001 in Moderate to Severe Plaque PsoriasisSlideshow (NASDAQ:ORKA) 2026-04-29 - Seeking Alpha
Oruka Therapeutics (ORKA) offers 9.66M shares, raising ~$658M net - Stock Titan
Oruka Therapeutics (NASDAQ:ORKA) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Moody Aldrich Partners LLC Takes $3.84 Million Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
H.C. Wainwright raises Oruka Therapeutics price target to $120 on trial data - Investing.com Canada
Oruka Therapeutics Shares Surpass Record High After Psoriasis Trial - HarianBasis.co
Oruka Therapeutics Prices Upsized $700 Million Share Offering - marketscreener.com
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $100 - Moomoo
Oruka Therapeutics prices $700M stock offering at $72.50/share By Investing.com - Investing.com Australia
Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering - The Manila Times
Oruka Therapeutics prices $700M stock offering at $72.50/share - Investing.com
Oruka Therapeutics, Inc. Prices Upsized Public Offering of 9.66 Million Shares at $72.50 Per Share - Quiver Quantitative
Oruka Therapeutics announces pricing of upsized $700 million underwritten public offering - marketscreener.com
Biotech Oruka locks in $700M cash raise at $72.50 a share - Stock Titan
Oruka Therapeutics Announces Pricing Of Upsized $700 Million Underwritten Public Offering - TradingView
Oruka Therapeutics (NASDAQ:ORKA) Trading 6.6% HigherWhat's Next? - MarketBeat
ORKA stock is soaring after psoriasis trial results — here's why BTIG hiked its price target by 94% - MSN
OGN Soars 16.87%, ORKA Hits Record on Healthcare Catalysts - Gotrade
UBS Lifts Price Target on Oruka Therapeutics to $100 From $75, Maintains Buy Rating - marketscreener.com
Oruka reports positive data from Phase IIa trial for plaque psoriasis - Yahoo
Oruka Therapeutics stock hits 52-week high at 90.06 USD By Investing.com - Investing.com South Africa
Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis Dosing - MarketBeat
5 Stocks Racking Up Monster Gains - Insider Monkey
Oruka Therapeutics (ORKA) Hits Record High on Stellar Clinical Trial Result - Yahoo Finance
Oruka’s ORKA-001 achieves 63.5% complete skin clearance in trial - Investing.com UK
Oruka Therapeutics stock explodes as psoriasis data shows 'highly compelling' skin clearance - MSN
New data suggest Oruka’s IL-23 mAb could be competitive in psoriasis - BioCentury
Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million - TechStock²
Oruka Therapeutics (ORKA) seeks to sell common stock under shelf prospectus - Stock Titan
Oruka Therapeutics (ORKA) registers $500M shelf for stock and warrants - Stock Titan
Clear Street raises Oruka Therapeutics price target on trial results By Investing.com - Investing.com Canada
Oruka Therapeutics launches $500 million stock offering By Investing.com - Investing.com Australia
Oruka Therapeutics Inc (ORKA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):